- Half Year 2023 Poxel SA Earnings Call TranscriptSep 26, 2023€0.401 (-20.59%)Earnings
- Q4 2022 Poxel SA Earnings Call TranscriptMar 23, 2023€0.735 (-3.29%)Earnings
- Half Year 2022 Poxel SA Earnings Call TranscriptSep 21, 2022€2.08 (+1.96%)Earnings
- Full Year 2021 Poxel SA Earnings Call TranscriptMar 22, 2022€2.75 (+2.00%)Earnings
- Half Year 2021 Poxel SA Earnings Call(English) TranscriptSep 23, 2021€6.33 (+1.20%)Earnings
- Poxel SA New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Corporate Call TranscriptJul 12, 2021
- Full Year 2020 Poxel SA Earnings Call TranscriptMar 25, 2021€6.68 (-0.30%)Earnings
- Poxel S.A. - Special Call TranscriptDec 14, 2020
- Poxel S.A. - Special Call TranscriptOct 01, 2020
- Half Year 2020 Poxel SA Earnings Call TranscriptSep 15, 2020€6.47 (+4.35%)Earnings
- Full Year 2019 Poxel SA Earnings Call TranscriptMar 26, 2020€6.88 (+18.21%)Earnings
- Poxel SA - Special Call TranscriptDec 20, 2019
- Poxel SA - Special Call TranscriptNov 26, 2019
- Half Year 2019 Poxel SA Earnings Call TranscriptAug 26, 2019€6.3 (-1.25%)Earnings
- Poxel SA - Special Call TranscriptJun 25, 2019
- Poxel SA - Special Call TranscriptApr 09, 2019
- Full Year 2018 Poxel SA Earnings Call TranscriptMar 21, 2019€7.87 (+0.38%)Earnings
Poxel S.A. - Special Call Transcript
Ladies and gentlemen, welcome to Poxel PXL770 Phase IIa Trial Results Announcement.
I now hand over the call to Mrs. Jonae Barnes, Senior Vice President, Investor Relations, Corporate Communications and Public Relations. Madam, please go ahead.
Good afternoon, everyone, and welcome to our conference call today to review the results from the PXL770 Phase IIa trial. I'm Jonae Barnes, Senior Vice President, Investor Relations, Corporate Communications and Public Relations. With me on the call, Thomas Kuhn, CEO; Pascale Fouqueray, Executive Vice President, Clinical Development and Regulatory Affairs; David Moller, Executive Vice President and Chief Scientific Officer; and Julie Dubourg, Medical Director, Clinical Development. They will all be available for Q&A after our call is complete.
Earlier today, we issued a press release for the PXL770 Phase IIa results. For those of you who don't have a copy, you can access it in the Investor Relations section of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)